Skip to content

Open Label Trial of NanoDOX Hydrogel in Orthopedic Trauma Wounds With and Without Vacuum Assisted Closure Therapy

A Prospective, Randomized, Open Label Trial of NanoDOX™ Hydrogel Plus Vacuum Assisted Closure Therapy Versus Vacuum Assisted Closure Therapy Alone in Orthopedic Trauma Wounds.

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01518491
Enrollment
0
Registered
2012-01-26
Start date
2012-04-30
Completion date
2012-12-31
Last updated
2017-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopedic Trauma Wounds

Brief summary

The purpose of this study is to determine the effect of NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on the healing rates of open traumatic orthopedic and soft tissue wounds when compared to a serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.

Interventions

DRUGNanoDOX Hydrogel

NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy

OTHERVAC Alone

Patients will receive VAC therapy three time weekly for eight weeks

Sponsors

United States Department of Defense
CollaboratorFED
NanoSHIFT LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Be 18 years of age or older * Women of childbearing potential must have a negative urine pregnancy test at screening and at baseline * Agree to use a double-barrier method of contraception during their participation in this study * condoms (with spermicide) and hormonal contraceptives OR * condoms (with spermicide) and intrauterine device OR * intrauterine device and hormonal contraceptives OR * Abstains from sexual intercourse during their participation in this study * Is with a same-sex partner and does not participate in bisexual activities where there is a risk of becoming pregnant * Have a full-thickness trauma wound that is between 1.2cm2 and 24cm2 at initial screening * Be able to apply study drug to their wound, or have a reliable and capable caregiver do it * Subjects will have adequate blood flow to the wound as defined by transcutaneous oxygen tension (TcpO2) of \>30mmHg recorded over intact epidermis at the wound margin.

Exclusion criteria

* Less than 18 years of age * Pregnant or lactating woman or a female of childbearing potential who is not practicing acceptable form of birth control. * Allergic to tetracycline, minocycline, demeclocycline, or any other known tetracycline derivative * Tested positive for a doxycycline-resistant infection * Have undergone treatment with systemic corticosteroid or immunosuppressive therapy in the past 2 months * Currently undergoing dialysis for renal failure * Have participated in another clinical research trial within the last 30 days * Subject has wounds resulting from any cause other than trauma (diabetes, electrical burn, arterial insufficiency, chemical or radiation insult) * Active or previous (within 60 days prior to the study screening visit) chemotherapy * Active or previous (within 60 days prior to the study screening visit) radiation to the affected wound area to be treated by investigational drug or placebo * Physical or mental disability or geographical concerns (residence not within reasonable travel distance) that would hamper compliance with required study visits * The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including the shock wave treatment procedure, standard-of-care self-care requirements, and all study-related follow up visit requirements. * History of sickle cell anemia * History of infection with Human Immunodeficiency Virus * History of other immunodeficiency disorders * Severe anemia - Hgb \< 7 g/dl (males) or \< 6.5 (females)

Design outcomes

Primary

MeasureTime frameDescription
Determine the effect of NanoDOX Hydrogel on the healing rates of open traumatic orthopedic wounds with and without vacuum assisted closure therapy.participants will be followed for up to eight weeksTo determine the effect of NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on the healing rates of open traumatic orthopedic and soft tissue wounds when compared to a serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.

Secondary

MeasureTime frameDescription
Analyze the molecular changes in proinflammatory cytokine levels and bioburden that occur in traumatic orthopedic and soft tissue woundsparticipants will have three visits per week for up to eight weeksAnalyze the molecular changes in proinflammatory cytokine levels and bioburden (quantitative bacteriology and qRT-PCR for 16S rDNA) that occur in traumatic orthopedic and soft tissue wounds as a function of healing rate in the presence/absence of NanoDOX™ Hydrogel.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026